Moderna eyes M&A with COVID cash To view this email as a web page,
click here Novavax's latest COVID-19 vaccine delay sends shares tumbling nearly 20% Kaiser Permanente, Ascension Health and 86 other health systems requiring mandatory COVID-19 vaccines for their workforces Moderna is ready to spend billions in COVID-19 cash, and the famed biotech has sights set on gene editing COVID-19 tracker: J&J shot protects against severe Delta cases; FDA working quickly on booster plans Telehealth provider Cadence debuts with $41M to bring hospital care home Illumina posts 78% revenue growth as cancer, DNA testing ramp back up Featured Story | By Kyle LaHucik Novavax hit another roadblock in its COVID-19 vaccine journey in the U.S., with the company pushing back an FDA filing from May to July to now the fourth quarter. The company filed in India, Indonesia and the Philippines this week, and expects more submissions later this year with WHO, UK, EU, Australia, Canada and New Zealand. read more |
| |
|---|
|
Top Stories By Dave Muoio COVID-19 vaccination as a condition of employment has picked up the support of numerous industry and professional organizations. More health systems are taking a hard stance. read more By Annalee Armstrong Moderna has found a direction to volley its mountain of COVID-19 vaccine cash: gene editing. Executives revealed during a second-quarter earnings call Thursday that Moderna is ready to “expand our horizons” with external technologies or products. Read: They’re ready to start buying. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner In a large trial in South Africa, Johnson & Johnson's vaccine protected healthcare workers from severe disease associated with the troublesome Delta variant. Meanwhile, the FDA is working quickly to develop its plans on COVID-19 vaccine boosters. Plus more headlines. read more By Conor Hale With the emergency of the COVID-19 pandemic illustrating telehealth's benefits, a new company called Cadence hopes to keep hospitals moving to the beat of the same drum. read more By Conor Hale In something of an understatement, Illumina CEO Francis deSouza said a 78% increase in second quarter sales over 2020 “significantly exceeded expectations” and has pushed the sequencing giant to raise its financial guidance for the remainder of the year. read more |
|
